Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Shahrokh F ShariatTakahiro KimuraKeiichiro MoriHirotaka SuzukiTakayuki SanoTakashi OtsukaYuya IwamotoWataru FukuokayaKeiichiro MiyajimaYuki EneiKeigo SakanakaAkihiro MatsukawaHajime OnumaKoki ObayashiShunsuke TsuzukiKenichi HataTatsuya ShimomuraJun MikiShin EgawaPublished in: The Prostate (2021)
Despite limitations regarding the time-dependent bias, ADT with abiraterone acetate significantly prolonged the time to CRPC compared to bicalutamide in patients with high-risk mHSPC. However, further study with longer follow-up is needed.